Purpose of Review The structural damage caused by rheumatoid arthritis (RA) can often be mitigated by orthopaedic surgery in late disease. This study evaluates the value of predictive factors for orthopaedic intervention. Methods A systematic review of literature was undertaken to identify papers describing predictive factors for orthopaedic surgery in RA. Manuscripts were selected if they met inclusion criteria of cohort study design, diagnosis of RA, followup duration/disease duration ≥3 years, any orthopaedic surgical interventions recorded, and then summarised for predictive factors. A separate predictive analysis was performed on two consecutive UK Early RA cohorts, linked to national datasets. Recent Findings The literature search identified 15 reports examining predictive factors for orthopaedic intervention, 4 inception, 5 prospective and 6 retrospective. Despite considerable variation, acute phase, x-ray scores, women and genotyping were the most commonly reported prognostic markers. The current predictive analysis included 1602 procedures performed in 711 patients (25-year cumulative incidence 26%). Earlier recruitment year, erosions and lower haemoglobin predicted both intermediate and major surgery (P<0.05). Summary Studies report variations in type of and predictive power of clinical and laboratory parameters for different surgical interventions suggesting specific contributions from different pathological and/or patient-level factors. Our current analysis suggests that attention to non-inflammatory factors in addition to suppression of inflammation is needed to minimise the burden of orthopaedic surgery.
Introduction
Physicians rely on markers of disease severity for making management decisions in RA. Many studies have examined risk factors for joint damage as measured on radiographs, and standard measures of active disease have been featured in most of these [1] [2] [3] . There are fewer reports on structural damage as measured by need for orthopaedic surgery, mainly because such studies require long follow-up and large sample sizes, previously difficult to achieve in inception cohort studies [4, 5] .
Several factors other than joint pathology contribute to decisions to undergo surgery, including patient choice, severity of reported pain, comorbidities, accessibility of health resources and orthopaedic surgery. Clinicians would benefit from reliable predictors of subsequent joint surgery in RA, and whether these differ from radiological joint damage, in order to identify reversible risk factors for treatment strategies and to prioritise research in these patients.
The objectives of this study were (i) to explore prognostic factors for orthopaedic intervention in RA reported in the literature and (ii) to identify the most powerful combination of predictive factors for orthopaedic surgery over 25 years in two large ongoing prospective observational studies from the UK.
Methods Systematic Review
A systematic review protocol was developed to ensure that objectives and aims where clearly outlined from outset and submitted and approved by PROSPERO. Publications describing predictive factors for orthopaedic surgery in patients with RAwere identified by computerised searches of Medline, PubMed, Cochrane Library (incl CENTRAL, CDSR, DARE, HTA) and Scopus supplemented by lateral search techniques: checking reference lists, key word searches in Google Scholar and 'cited by' option in PubMed. In addition, lateral search techniques, such as checking reference lists, performing key word searches in Google Scholar and using the cited by option in PubMed, were used. All databases were searched from January 1, 1975 to February 31, 2015 . The search strategy used a mixture of key words and MeSH terms on the title/ abstract and full text as appropriate.
The Manuscripts were selected for review if they met the following inclusion criteria: prospective or retrospective cohort study design, physician or ARA or ACR or EULAR diagnosis of RA, follow-up duration/disease duration ≥3 years, predictive factors for any orthopaedic surgical interventions recorded.
UK RA Orthopaedic Datasets
We used two well-described multi-centre UK inception cohorts of RA patients recruited prior to DMARD use, the Early RA Study (ERAS, 9 rheumatology centres in England between 1986 and 1999) and the Early RA Network (ERAN, 23 in England, Wales and Ireland from 2002 to 2010) [6•] . Numbers and median follow up was 1465 and 10 years (maximum 25 years) and 1236 and 6 years (maximum 10 years) respectively. Time to first DMARD following baseline assessment was 2 and 1 month. Median time from symptom-onset to first visit was 6 months in each cohort.
These consecutive cohorts had very similar design and modes of data collection allowing combined analysis. In view of reports of greater predictive value of first year variables [5, 7] , both baseline and first year standard parameters have been included [6•] . All centres followed the framework of published UK guidelines for management of RA, which included mainly sequential DMARDs in ERAS, standard UK practice for early RA in the 1980s/1990s [6•] . ' Step-up/add-on' combination therapies were initially reserved for more severe RA only but gradually became more common [8] . In ERAN, more frequent earlier use of combination DMARDs and biologics were employed in line with contemporary UK guidelines [9] .
Data linkage to national sources was performed through unique NHS number and included Hospital Episode Statistics (HES), which provides information on all National Health Service (NHS) orthopaedic interventions in England, and the National Joint Registry (NJR) which contains information on hip, knee and ankle joint replacement surgery across both the NHS and independent healthcare sectors, as previously documented in greater detail [6•] . Orthopaedic interventions undertaken after the diagnosis of RA were categorised by joint type and procedure as previously described [5, 6•] . Major: primary or secondary large joint replacement surgery. Intermediate: wrist, hand, hind/fore-foot joint reconstructive procedures (excision arthroplasty, synovectomy, arthrodesis). Minor: soft tissue procedures (e.g. tendon surgery). Minor procedures are omitted from this report due to their wide heterogeneity and lack of statistically significant findings from predictive analysis.
Statistical Analysis
Survival analysis was used to examine predictive values of variables for time to first orthopaedic intervention. Cox regression, the most widely used method of survival analysis, can produce biased effect estimates in the presence of competing risks, such as death, using non-informative censoring methods. Because of the large number of deaths over the 25-year study period, competing-risks regression was used, which accounts for patient follow-up, with the event defined as first orthopaedic intervention and competing risk defined as death. Patients who did not experience either of these events were censored at end of 2011. Separate models were estimated for intermediate and major surgery, total hip (THR) and knee replacement (TKR). The models employed absolute values of variables, first at baseline then at 1 year.
The following were entered into the model as core covariates of interest, given their importance in RA: gender, age at disease-onset, recruitment year, time to diagnosis at baseline, rheumatoid factor (RF), BMI, HAQ, disease activity score (DAS) based on the original DAS (ERAS) and modified DAS28 (ERAN) [10] , and its individual components including tender (TJC) and swollen joint counts (SJC), patientreported visual analogue scale (VAS), haemoglobin, ESR, hands and feet x-rays assessed for erosions by each centre (Larsen scores were available in a subgroup of 70% of ERAS patients as previously described) [3] . As baseline and 1-year variables did not differ significantly in these patients (data not shown), subgroup analysis included Larsen scores.
In order to establish other covariates to include in the model, univariate analysis was undertaken (results not shown). Those significant to p < 0.01 were also included. In further models, DAS and the proportion of DAS attributable to patient-reported components (TJC and VAS) termed DAS-P were also examined [11] . DAS and DAS-P were only weakly correlated (r < 0.50) and so were included together. Overall, missing baseline data were infrequent (around 5%), unlikely to introduce bias. Sensitivity analysis was performed to test robustness of multivariate models by excluding variables with missing data both separately and together in the models (see supplementary material). To assess variance and predictive strength of the regression models, the pseudo R 2 and area under the curve (AUC) were examined for baseline and 1-year models. Those variables with 10-year follow-up were entered as time-varying covariates (TVCs), where missing data were imputed using multiple imputation techniques to test the assumption of proportionality over time. Finally, to investigate predictors of multiple surgeries, negative binomial regression was used on the total major or intermediate interventions. All analysis was conducted using Stata (version 13) with significance level of p < 0.05 assumed.
Results

Systematic Review
The literature search initially identified 954 possible relevant paper based on their titles. From these, we identified 128 abstracts which appeared to fulfil the appropriate criteria, 39 of which were worthy of full-text review. Only 15 reports examined predictive factors for orthopaedic intervention in 17 RA cohorts, 4 inception, 5 prospective and 6 retrospective. Five were not included because although all were reviews of orthopaedic outcomes in RA, they did not in fact report on predictive factors. There was considerable variation in study recruitment decades and cohort designs, especially in length of follow up and time to surgical intervention from onset of RA. Most reports distinguished between all surgical interventions and total joint replacements (TJRs), only a few reporting on differences between specific types of surgery. Although there was some variation in the parameters examined for predictive value, most reports included clinical measures of joint disease activity (joint scores, DAS), laboratory acute phase (ESR, CRP), RF and x-ray scores. Some included socioeconomic and functional measures (e.g. HAQ), HAEMOGLOBIN and genotyping (HLA DR4 and SE). Acute phase, x-ray scores, women and HLA SE were the most commonly reported prognostic markers, RF cited only uncommonly. The 15 reports are summarised in Appendix 1, Table A.1.
Predictive Analysis of UK Datasets
During the 25-year observation period, 711 patients from a total of 2701 had undergone at least one type of orthopaedic intervention (n = 1602, 25-year cumulative incidence (CI) 26.4%). The 25-year CI, adjusted for death as competing risk, for any major intervention was 22% (95%CI [19] [20] [21] [22] [23] [24] and that for any intermediate intervention was 22% (95%CI 18-26) (Fig. 1) . The different types and frequency of orthopaedic interventions and a summary of baseline and 1-year characteristics of patients having surgery are shown in Appendix 1, Tables A.2 and A.3. Competing risk regression analysis (Table 1) showed that the risk of both major and intermediate surgeries was reduced in more recent study recruitment years by 6% (SHR 0.94, 95%CI 0.90-0.98) and 7% (SHR 0.93, 95%CI 0.88-0.98), respectively. Older age at disease onset predicted major intervention (SHR 1.01), and female gender more than doubled the risk for intermediate surgery compared to males (SHR 2.11), although not for major surgery. Lower BMI and haemoglobin predicted intermediate surgery in both baseline and 1-year models. Higher VAS or lower ESR at baseline, or higher HAQ or TJC at 1 year, each predicted intermediate surgery.
The higher the haemoglobin or the lower the HAQ at 1 year, the lower the risk of major surgery. Higher HAQ at 1 year (Table 1) Higher baseline TJC carried an increased risk, whereas increased SJC at 1 year reduced the risk of major surgery.
High TJC and low SJC might indicate abnormalities of central pain processing, rather than inflammatory disease activity [11] . To explore this further, we examined additional statistical models in which the separate DAS components were replaced by DAS and DAS-P. The results are summarised in Supplementary Data, Appendix 1.
Multiple Intermediate and Major Orthopaedic Interventions
Predictors of multiple surgeries (defined as two or more major or intermediate surgeries) using negative binomial regression are shown in Supplementary Data, Appendix 1, Table A.4. Modelling multiple surgical outcomes per patient yielded similar associations to those observed for single first events. Very similar ratios and significant levels were seen for the same predictive variables. Sensitivity analysis on the small proportion of patients who had both major and intermediate surgery showed no difference in effects between surgery types.
Discussion
In this systematic review, most studies examining RA outcomes by 5 years reported orthopaedic intervention in around 15%, increasing to around 25% in 20 years+ follow-up cohorts. These figures were confirmed by our detailed analysis of a large UK inception cohort. Orthopaedic surgery is an important means of assessing medium to long-term outcomes in RA and is considered both a surrogate marker of joint damage [12] and provides data on unsuccessful medical treatment in RA [13] . Covering both the pre-and post-biologic eras, this systematic review and the analysis of orthopaedic interventions in two well-established RA inception cohorts has found consistency in certain predictive factors and considerable variation in others.
Although few studies distinguished between types of interventions, most reported that women had a higher risk for surgery. In our current analysis, this was so for intermediate surgery only, suggesting either more severe disease in women or different thresholds for surgery. Hand surgery in women might be work-related, as in administrative/typing roles, fabrics and Competing-risks multivariate predictive model *p < 0.05; **p < 0.01; ***p < 0.001 kitchen work, and is subject of another study currently being undertaken. Other possibilities include lower thresholds for surgery stemming from differences in psychological, pain, functional and cosmetic perceptions.
Age was not a consistent marker although the predictive analysis found an increased risk of major surgery in patients older at disease onset. Average age of RA onset has increased in recent decades, and later studies may reflect an increased need for orthopaedic surgery. In the predictive analysis study, recruitment year also had an effect, with more recent years predicting lower risk of surgery, most likely reflecting the impact of improved management of RA on outcome, as we have reported recently [6•] .
There was fair consistency in the ability of certain clinical and laboratory measures at early stages of RA to predict the eventual need for orthopaedic surgery, including mainly acute phase and radiographic damage. Some studies reported that haemoglobin and genotyping had additional clinically useful predictive value. Some studies reported variations in type of, and predictive power of, clinical and laboratory parameters for different surgical interventions suggesting specific contributions from different pathological and/or patient-level factors. Attention to non-inflammatory factors in addition to suppression of inflammation may be needed to minimise the burden of orthopaedic surgery.
One quarter of patients presenting with RA underwent major or intermediate orthopaedic surgery during the following 25 years. We have demonstrated that baseline and 1-year clinical and laboratory variables have clinically useful and independent predictive value for eventual orthopaedic surgery. Similar risk factors for joint destruction as measured on Xray have been identified, mainly standard measures of active disease [1] [2] [3] . However, some unexpected findings have emerged.
Early radiographic damage and low haemoglobin predicted both intermediate and major surgery, whereas variations in predictive power of other parameters for the different surgical interventions suggest specific contributions from different pathological and/or patient-level factors. Erosions at 1 year were predictive for both major and intermediate surgery, although at baseline, they were only predictive for major surgery. Baseline variables including erosions are pre-DMARD therapy in these cohorts and might not adequately reflect potential response to treatment. Joint damage at 1 year reflects suboptimal response to treatment. Patients with progressive damage despite exposure to treatment are more likely to require subsequent orthopaedic surgery than those in whom therapy has retarded progression. One-year measurements may therefore be better predictors of long-term outcomes in RA than baseline, prior to effective treatment [6•, 7] . The subanalysis of Larsen scores in ERAS supports this, showing stronger predictive value of Larsen at 1 year (p < 0.001) compared to baseline (p < 0.05). A similar explanation could apply for prediction of major and intermediate surgery by HAQ at 1 year only. Prompt and intensive treatment of patients with early RA might be expected to not only improve outcomes but also permit earlier more accurate prediction of surgical outcomes.
One of the most striking findings in our current analysis was the predictive value of haemoglobin for both major and intermediate surgery, independent of other variables of active disease, the predictive effect being strongest with haemoglobin at 1 year for major surgery. Our findings support the two previous reports that haemoglobin predicts orthopaedic intervention, during the first 5 years after diagnosis [5] , and over 25 years follow up in established arthritis [13] . It is well established that low haemoglobin is a marker of inflammatory disease activity. People with RA display a blunted response to erythropoietin [14] , and erythropoietin treatment has been associated with a reduction in inflammatory activity [15, 16] , and effective suppression of inflammation is associated with increases in haemoglobin, suggesting a tight coupling between inflammatory activity and haematopoiesis. Iron metabolism might, in addition, be directly involved in joint damage in RA. Higher iron deposition and iron-complexes in synovial fluid and membranes have been associated with decreases in peripheral blood haemoglobin levels during active RA [17] , and iron deposition is associated with accelerated joint damage in haemochromatosis.
Although associations with active inflammation may contribute to the overall predictive power of haemoglobin for orthopaedic surgery in RA, another report [18•] supports our findings that anaemia-related progression of joint damage might not be restricted to patients with clinically active disease. Non-inflammatory mechanisms might also mediate associations between low haemoglobin and subsequent orthopaedic surgery. Low haemoglobin may also be related to chronic NSAID use, which has been associated with increased joint damage [19] [20] [21] . Unfortunately, data on cumulative NSAID use were not available for our cohorts. Whatever the underlying mechanism, our data support the inclusion of haemoglobin in predictive models for joint surgery, in addition to standard measures of inflammation.
We found that different DAS components had opposing predictive values for subsequent orthopaedic surgery, a possible explanation for the weak predictive value of total DAS. Higher TJC at baseline and 1 year had positive predictive value for intermediate joint surgery. SJC at 1 year had the opposite effect, reducing the risk of major surgery. These findings suggest that patient-reported symptoms (pain and tenderness) might be stronger drivers for joint surgery, whereas high objective measures of synovitis might result in surgery being postponed or averted while further attempts are made to suppress inflammatory disease activity. Consistent with this, we found that DAS-P (but not DAS) had positive predictive value for intermediate surgery.
Associations between clinical inflammation and joint damage in RA are often weak and inconsistent [22] [23] [24] , in part due to the limited sensitivity and specificity of clinically detected synovitis to predict the presence or activity of synovial pannus [25] . Clinical measurement of disease activity usually depends on composite scores such as DAS, which combine patientreported (VAS and TJC), physician observed (SJC) and laboratory (ESR or CRP) components. Although each of these components increases with increasing inflammatory activity in RA, individual components may reflect different underlying pathological mechanisms. In particular, it has been proposed that VAS and TJC, or the proportion of DAS attributable to these components (DAS-P), might be more influenced by central pain mechanisms, whereas SJC and ESR might be more directly associated with inflammatory disease activity [26] .
Discrepancies in predictive values of joint scores for hand/foot versus major joint replacement surgery could be due to a number of other factors: higher joint scores can be achieved in hands and feet compared to large joints, in which synovitis may be less easy to detect; not all joints are included in DAS (e.g. hips); the more demanding nature of major joint surgery can lead to higher thresholds for intervention, not necessarily driven by patient symptoms; higher SJC may lower thresholds for more intensive medical therapies.
Despite an apparently protective effect of high BMI on intermediate surgery, high BMI predicted increased likelihood of major orthopaedic surgery. The influence of BMI on disease activity in RA is unclear. Some studies have shown protective effects of higher BMI, with lower BMI associated with higher disease activity [27] , increased erosions, more severe systemic RA (cachexia) and reduced survival [28, 29] . Other studies have shown obesity an independent risk factor for impaired quality of life in RA and poor disease outcomes [30] .
A strong link between obesity and knee osteoarthritis is well-recognised [31] , although reports on the predictive value of high BMI for large joint surgery vary for OA [32] and RA [33] . High BMI may increase loading on already compromised joints and be associated with OA through genetic or metabolic mechanisms [34] . Such mechanisms may be discrete from those leading to intermediate orthopaedic surgery.
Our current study complements existing data as identified through our literature search. Strengths of our current predictive analysis include the "real-life" setting of ERAS and ERAN, reflecting the therapeutic practices of both pre-and post-biologic treatment decades; length of study follow up; low attrition rates for orthopaedic data through HES and corroboration and extension of source data by linkage to national datasets. The use of modern statistical techniques, in particular competing risk regression, has enabled maximum use of data and accounted for both the event of interest (orthopaedic surgery) as well as death allowing for more precise estimates of the effects of independent variables. Although our observational study design allows identification of associations between baseline variables and orthopaedic interventions, defining causal factors is not possible, especially in the absence of a control group, or placebo-controlled interventions. As allocation of treatment in our study was not randomized, it is possible that the resulting imbalance in underlying risk profiles could introduce bias (confounding by indication) [35] . Lack of treatment randomisation precluded adequate investigation of possible effects of steroids and DMARDs on surgical rates, unavoidable in observational studies [6•, 36] , but the presence of widely adopted UK treatment guidelines and the examination of baseline and 1-year variables only should minimise this bias.
Another potential limitation is case definition, i.e. what is considered 'RA-related' joint surgery, since coincidental pathophysiological processes, including osteoarthritis and fracture, might have been the main triggers for orthopaedic intervention. Separate analysis of RA-related and unrelated orthopaedic procedures is not possible, due to difficulties with case definition and potential interactions. RA patients who undergo TKR surgery usually display osteophytes on plain radiographs, but also display more intense synovitis than those undergoing surgery for OA alone [37] . There are currently no definitive classification criteria that permit valid discrimination between OA secondary to RA and comorbid primary OA. Indeed, even in those with primary OA, comorbid inflammatory synovitis might increase rates of structural progression and hasten the need for major joint surgery [38] . Patients with RA, by merit of already being under specialist care, might have facilitated access to orthopaedic surgery even for comorbid conditions.
Generalising our findings to other healthcare systems requires caution, although they have been enhanced by data collection within a nationalised (UK) health service, with extensive linkage to national databases. Finally, we cannot exclude other possible important contributions to prediction of orthopaedic surgery from factors not measured in our cohorts. Future studies should also examine both the cumulative effects of disease markers over time, and also possible associations between orthopaedic intervention and patient-centred outcomes such as work disability.
Conclusions
This report provides information that could be used for planning future healthcare provision of orthopaedic surgery, in light of the changing prevalence and characteristics of early RA, increasing prevalence of obesity, and an ageing population. Our findings point to multiple and complex mediators of future orthopaedic surgery in people presenting with RA, suggesting that interventions additional to the control of inflammatory disease may be important in minimising the burden of orthopaedic surgery for patients and healthcare systems in the future. Predicting even late joint destruction and need for surgery up to 25 years later is possible and more accurate at 1 year of therapy, rather than at the time of RA diagnosis. EULAR recommendations [39] emphasize the importance of early intervention with DMARDs followed by biologics if response is insufficient. Most of the predictive factors identified through previous studies as well as current analysis are potentially reversible with appropriate therapy. It is postulated that stratifying therapies based on these prognostic factors measured at 1 year could further reduce the structural damage that leads to orthopaedic intervention up to 25 years later.
